Michael Gelband’s Keros Therapeutics KROS Stock Holding History

Michael Gelband’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,360	Closed	-$272K	–	1841
2025 Q4	$272K	Sell	13,360 -9,615	-42%	-$169K	﹤0.01%	1330
2025 Q3	$363K	Buy	+22,975	New	+$339K	﹤0.01%	1256
2025 Q2	–	Sell	-18,976	Closed	-$193K	–	1732
2025 Q1	$193K	Buy	+18,976	New	+$220K	﹤0.01%	1303
2024 Q3	–	Sell	-19,940	Closed	-$911K	–	1860
2024 Q2	$911K	Buy	+19,940	New	+$1.07M	0.01%	1054
2023 Q1	–	Sell	-11,823	Closed	-$568K	–	1954
2022 Q4	$568K	Buy	+11,823	New	+$552K	0.01%	1125
2021 Q4	–	Sell	-15,952	Closed	-$631K	–	2396
2021 Q3	$631K	Buy	+15,952	New	+$568K	0.01%	1261

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Michael Gelband's KROS Position: Q1 2026 in Review

Michael Gelband sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 13,360 shares — an estimated $272K sold.

Michael Gelband first reported a position in KROS in Q3 2021 and held it in 6 quarters. The position peaked at $911K in Q2 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

Michael Gelband reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
Michael Gelband sold 13,360 Keros Therapeutics shares in Q1 2026, an estimated $272K.
Michael Gelband first reported a position in Keros Therapeutics in Q3 2021 and held it in 6 quarters.
Michael Gelband's Keros Therapeutics position peaked at $911K in Q2 2024.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.